Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention (ABCD-PCI)
26 juli 2011 bijgewerkt door: Icahn School of Medicine at Mount Sinai
Ambulatory Closure Device Percutaneous Intervention: a Multi-Center Randomized Trial Evaluating Patient Satisfaction, Safety, and Cost Effectiveness of Ambulatory PCI in the Current Era
This is a multi-center trial that will evaluate the safety, feasibility, and cost effectiveness of discharging patients, who have had successful percutaneous coronary intervention (PCI) and deployment of the AngiomaxTM closure device, 6 hours after against 24 hours after the procedure.
Patients will be randomized in a 3 (test): 1 (control) fashion and will have a study population of 600 patients over 6 investigational sites all within the United States.
Patients <65 years old will be chosen in order to stay within the low risk group and will be followed up after 24 hours, 7 days, and 30 days via phone or office visit.
The primary endpoint will be a composite of major adverse cardiac and cerebral events, and the incidence of major bleeding or vascular complications.
Data acquired from the study, such as blinded financial information and patient satisfaction surveys, will be used in order to evaluate cost analysis and safety of the procedure.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Closure devices are a relatively new method for sealing the femoral arterial puncture following procedures including percutaneous intervention (PCI).
Because the risk of severe complications (e.g., bleeding, myocardial infarction, stroke, and mortality) associated with PCI when closure devices are very low, many patients undergoing PCI may be considered eligible for a same day hospital discharge.
As the practice of ambulatory PCI is becoming more common, it is important to evaluate the readiness of patients under-going PCI for same-day discharge and anxiety and coping abilities of patients post-discharge.
Our hypothesis is that same day discharge of patients who have undergone a PCI procedure with closure using a vascular closure device is safe, patients will be comfortable with a same day discharge and this process will be more cost efficient than the current standard of staying in the hospital overnight.
The current pilot study is a multi-center, randomized parallel arm, controlled trial of low-risk patients undergoing an elective PCI procedure.
Overall, 600 patients will be enrolled.
After providing informed consent, participants will be randomized to leave the hospital on the same day as the PCI procedure or stay overnight in a 1:1 ratio.
Data collection includes a self-administered questionnaire at hospital discharge, telephone interviews at 7-days and 30-days post-hospital discharge, and chart abstraction.
The primary outcome for this study is differences across randomization arm in patient satisfaction scores on the validated 10-item Post-discharge coping difficulty scale assessed 7 days post-discharge.
Secondary outcomes will include differences across randomization group for symptoms of anxiety, readiness for hospital discharge, patient satisfaction with the timing of their discharge, post-procedure pain and soreness, and cost-savings.
While a data safety monitoring board will track all adverse events (i.e., myocardial infarction, hematoma, hospitalizations, and mortality), we anticipate too few events to occur to make meaningful inferences beyond that PCI is safe regardless of the timing of hospital discharge.
The data from this pilot study will determine the comfort patients experience after undergoing PCI with an ambulatory (i.e, same-day) hospital discharge.
Furthermore, this pilot study will provide the foundation for a large scale non-inferiority study of same-day discharge on outcomes including myocardial infarction, bleeding, and mortality.
Such data will indicate the overall feasibility of early ambulatory PCI and has the potential to radically alter health care delivery following PCI.
Studietype
Observationeel
Inschrijving (Werkelijk)
303
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Mount Sinai School of Medicine
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75226
- Baylor University Medical Center
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 75 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Bemonsteringsmethode
Kanssteekproef
Studie Bevolking
The target population for this study will include patients undergoing an elective PCI.
Overall, 600 patient will be recurited from two sites in the United Sates.
As this is a feasiblity study, enrollment will be restricted to low-risk patients.
For this reason, the study will be limited to patients under 75 years of age.
All patients must meet all of the inclusion criteria and have none of the exclusion criteria to be enrolled into the study.
Beschrijving
Inclusion Criteria:
. <75 years of age at the time of procedure.
2. Patient has a type A or B lesion(s)
3. Femoral access site is amenable to closure with a vascular closure device.
4. Over 2 hours since the completion of the PCI procedure (at least 2 hours must elapse from completion of the PCI before subjects become eligible).
Exclusion Criteria:
- Patient has a life expectancy less than 12 months.
- Patient has recent evidence of an acute coronary syndrome (MI)
- Femoral access is difficult or site is not amenable to closure device
- Anticoagulants other than unfractionated heparin or bivalirudin were used during the procedure (i.e. enoxaparin).
- Patient has sub optimal angiographic outcome or clinical complication(s) during PCI
- The PCI occurred in something other than a native coronary artery
- Angiographic evidence of thrombus
- Patient has more than 3 stents implanted during this PCI
- Patient has an INR >2, Platelet count <100,000 or Hematocrit <25
- Occlusion of major side branch during PCI of >1.5mm
- Patient has ejection fraction ≤30%
- Known allergy to PCI procedural medications
- Patient reports living further than 30 minutes from a hospital by ambulance.
- Patient provides informed consent and agrees to the follow-up schedule.
- Evidence of vascular complication(s) (e.g. dissection, hematoma, bleeding) peri-procedure
- Patient is pregnant
- Evidence of infection (e.g. fever, pus, swelling) peri-procedure
- Patients with chronic renal insufficiency (e.g. serum creatinine ≥1.5 mg/dL)
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Case-control
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
overnight
Subjects that stay overnight at the hospital.
|
At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day.
Randomization will occur in a 1:1 ratio.
Additionally, randomization will be performed stratified by study site.
|
|
Next Day Discharge
Subjects that are discharged on the same day of the procedure.
|
At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day.
Randomization will occur in a 1:1 ratio.
Additionally, randomization will be performed stratified by study site.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Post-hospitalization patient satisfaction
Tijdsspanne: 30 days after enrollment
|
The primary endpoint is the difference in post-hospitalization patient satisfaction during the initial seven days following PCI.
Post-hospitalization patient satisfaction will be assessed using the 10-item Post-Discharge Coping Difficulty scale.
|
30 days after enrollment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Patient satisfaction with timing of discharge
Tijdsspanne: 30 days after enrollment
|
Secondary outcomes will include post-hospital anxiety, readiness for hospital discharge, patient satisfaction with the timing of their discharge, post-procedure pain and soreness, resource utilization and cost-savings.
|
30 days after enrollment
|
|
Patient Satisfaction Outcome Assessment
Tijdsspanne: 30 days After Enrollment
|
These outcomes will be assessed using standardized questionnaires and validated techniques.
The composite of major adverse cardiac events (MACE) and cerebral events and the incidence of major bleeding or vascular complications will be monitored for all patients through the 30 day follow-up period.
|
30 days After Enrollment
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Michael C Kim, MD, Icahn School of Medicine at Mount Sinai
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 januari 2008
Primaire voltooiing (Werkelijk)
1 juni 2010
Studie voltooiing (Werkelijk)
1 juni 2010
Studieregistratiedata
Eerst ingediend
31 maart 2010
Eerst ingediend dat voldeed aan de QC-criteria
27 oktober 2010
Eerst geplaatst (Schatting)
29 oktober 2010
Updates van studierecords
Laatste update geplaatst (Schatting)
28 juli 2011
Laatste update ingediend die voldeed aan QC-criteria
26 juli 2011
Laatst geverifieerd
1 juli 2011
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- GCO 07-1324
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .